News

For Immediate Release: October 17, 2016

Contact
Mary Kuramoto
513-579-9911 x2523
m.kuramoto@medpace.com

Medpace Hosts Complimentary Webinar Oncology Trial Recruitment: Challenging Indications and Challenging Studies

CINCINNATI, OH — (October 17, 2016) – Medpace experts Lyon Gleich, MD, Jennifer L. Cutter, PhD, and Ross Ezzati, BS, MBA, will engage in an interactive discussion on the complexities of oncology trial recruitment and how to overcome them.

WEBINAR: Oncology Trial Recruitment: Challenging Indications and Challenging Studies

DATE: Tuesday, November 8, 2016

TIME: 11:30am ET/8:30am PT

DURATION: 1 Hour

REGISTER HERE

About the Webinar:

Oncology trials have always presented special challenges given the trial designs and oftencomplex inclusion exclusion criteria. As biotechs are developing more specialized novel therapies for oncology patients, whether a targeted therapy or an immuno oncology therapy, it is common that the development program requires a highly specific population to meet the regulatory goals. This may be due to an attempt to use the Accelerated Approval pathway or to achieve Breakthrough Designation for unmet medical needs, with even greater scrutiny of the ongoing program. This discussion will address the following:

  • Trial design challenges for specific oncology populations – Get the protocol right
  • Country and Site Selection considerations for the recruitment of challenging oncology studies
  • Facilitating patient recruitment across the study
  • Supporting the sites
  • Supporting the patient and caregivers

About the Presenters:

Lyon Gleich, M.D., Vice President, Medical Affairs, Oncology

Dr. Lyon Gleich serves as Vice President for oncology at Medpace and as a Medical Monitor brings extensive knowledge and experience to clinical trial design and management. He has provided medical leadership and strategy for oncology trials during his 10+ years at Medpace and his prior experience as a thought leader and Principal Investigator provides an excellent backdrop for sharing best practices.

Jennifer L. Cutter, PhD and Ross Ezzati, BS, MBA, Directors, Clinical Trial Management, Oncology

Jennifer and Ross oversee Medpace’s global oncology programs at Medpace and work collaboratively with the medical and regulatory affairs teams to accelerate clinical development. Their experience includes the management of oncology trials across multiple oncology patient populations. They each have 10+ years of clinical trial experience and have been at the forefront of the changing oncology trial management milieu.

ABOUT MEDPACE

Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people worldwide with operations in 35 countries.

For more information, please visit www.medpace.com